Status:
COMPLETED
Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Depression
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects.
Eligibility Criteria
Inclusion
- Healthy male 18-55
- Women not of child bearing potential, 18-55
Exclusion
- History of or current treatment for psychiatric illnesses, substance abuse or dependence
- History of a clinically significant neurological disorder (e.g., history of stroke, head trauma, etc.)
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00949767
Start Date
July 1 2009
End Date
March 1 2010
Last Update
January 25 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Uppsala, Sweden, 751 23